Abstract 754P
Background
Ubamatamab (REGN4018) is a mucin16 (MUC16) x CD3 bispecific antibody. Cemiplimab, an anti-PD-1 antibody, enhanced its activity in preclinical studies. In phase 1 (NCT03564340), ubamatamab monotherapy resulted in an acceptable safety profile and durable responses. We now present ubamatamab combined with cemiplimab dose escalation results.
Methods
Patients (pts) with recurrent platinum-experienced ovarian cancer (OC) received weekly intravenous (IV) ubamatamab at a dose range of 1–450 mg after initial step-up dosing. Cemiplimab 350 mg IV every 3 weeks was added beginning Day 29–36. Dose escalation initially followed a modified 3+3 design, then Bayesian optimal interval design. Primary endpoints were safety and PK. Secondary endpoints included confirmed objective response rate (ORR), Kaplan-Meier estimated duration of response (DoR) and progression-free survival (PFS) (RECIST 1.1), and CA125 response (GCIG).
Results
35 pts were enrolled, 29 (82.9%) received ≥1 dose of cemiplimab. Median number of prior therapies was 5 (range 1−10). Median duration of ubamatamab and cemiplimab exposure was 11 (range 2−75) and 12 (3−69) weeks, respectively. The most common treatment-emergent adverse events (TEAE) were pain (82.9%) and cytokine release syndrome (68.6%, all Grade [G] 1/2). The most common G≥3 TEAE were anaemia (25.7%), pain (20.0%) and neutropaenia (11.4%, 1 dose-limiting toxicity [DLT], 60 mg). Ubamatamab 1–250 mg weekly with cemiplimab was tolerable. In the highest dose cohort (450 mg), haemophagocytic lymphohistiocytosis (G4, DLT) was observed. Objective responses were observed at ubamatamab doses 10–250 mg (n=25). In 22 of these pts receiving ≥1 dose of cemiplimab, ORR was 18.2% (95% CI: 5.2–40.3), median DoR 8.3 months (4.2–not estimable), CA125 response rate 22.7% (7.8–45.4) and 6-month PFS 47.6% (25.7–66.7). Two pts with target lesion growth (+17%, +31%) before adding cemiplimab to ubamatamab had subsequent partial responses. Ubamatamab PK was not impacted by cemiplimab.
Conclusions
In pts with heavily pretreated OC, an acceptable safety profile and durable responses were observed with ubamatamab + cemiplimab. A randomised phase 2 expansion of ubamatamab +/- cemiplimab is ongoing.
Clinical trial identification
NCT03564340.
Editorial acknowledgement
Writing assistance was provided by Brian Head, PhD, of Regeneron Pharmaceuticals, Inc.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
R.E. O'Cearbhaill: Financial Interests, Personal, Other, Personal Fees: Bayer, Curio, Fresenius Kabi, Immunogen, MJH, Regeneron, Seattle Genetics, and Tesaro/GSK; Financial Interests, Personal, Other, Travel: Hitech Health ; Financial Interests, Personal, Advisory Board: GSK; Non-Financial Interests, Personal, Steering Committee Member: PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies; Non-Financial Interests, Personal, Advisory Role: Carina Biotech; Financial Interests, Institutional, Research Funding: AbbVie/StemCentrx, Atara Biotherapeutics, Bayer/Celgene/Juno, Genentech, Genmab/Seagen Therapeutics, Gynecologic Oncology Foundation , Kite Pharma, Ludwig Cancer Institute, Marker Therapeutics, Merck, Regeneron, Sellas Therapeutics, Syndax Pharmaceuticals, ; Financial Interests, Personal, Other, NRG representative: ComboMATCH study. K.N. Moore: Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): Alkemeres, Aravive, AstraZeneca, Blueprint Pharma, Caris, Eisai, Elevar, Genentech/Roche, GSK/Tesaro, Hengrui, IMab, Immunogen, Inxmed, Iovance, Lilly, Mereo, Mersana, Myriad, Novartis, Novocure, Tarveda, VBL Therapeutics and Verastem; Financial Interests, Institutional, Research Funding: AbbVie, Artios, AstraZeneca, Daiichi Sankyo, Genentech/Roche, GSK/Tesaro, Immunogen, Lilly, Merck, Mereo, Novocure, PTC Therapeutics and Regeneron. O. Yeku: Financial Interests, Personal, Advisory Board: Celldex, GIMV NV, hC Bioscience and TigaTx. J.F. Liu: Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): AstraZeneca, Clovis Oncology, Eisai, EpsilaBio, Genentech/Roche, GSK and Regeneron Pharmaceuticals, Inc.; Financial Interests, Institutional, Research Funding: 2X Oncology, Aravive, Arch Oncology, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, CytomX Therapeutics, GSK, Regeneron, Surface Oncology, Tesaro, Vigeo Therapeutics and Zentalis. S. Bouberhan: Financial Interests, Personal, Speaker, Consultant, Advisor: ImmunoGen. E.P. Hamilton: Financial Interests, Institutional, Research Grant: Regeneron, AbbVie, Acerta Pharma, ADC Therapeutics, Akesobio Australia, Amgen, Aravive, ArQule, Arvinas, AstraZeneca, AtlasMedX, Black Diamond, Boehringer Ingelheim, Clovis, Compugen, Curis, CytomX, Dana Farber Cancer Inst, Daiichi Sankyo, Deciphera, eFFE; Financial Interests, Institutional, Speaker, Consultant, Advisor: Arcus, Arvinas, AstraZeneca, Black Diamond, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera Pharmaceuticals, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo, Merck, Mersana, Novartis, Pfizer, Puma Biotechnology, Relay Therapeutics, Roc. S. Yoo, S. Govindraj, J. Brouwer-Visser, M. Peterman, T. Schmidt, B. Barnes, P. Madia, M. Zhu, T.S. Uldrick, E.A. Miller: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. D. O'Malley: Financial Interests, Personal, Research Funding: AbbVie, Agenus, Amgen, AstraZeneca, Celsion Corp, Clovis, Corcept Therapeutics, Eisai, GOG Foundation , Immunogen, Iovance, Janssen/Johnson & Johnson, Mersana, Novocure and Genentech/Roche, Regeneron, SDP Oncology (BBI), Seagen and Tesaro/GSK, Ajinomoto Inc., Array Biopharma, Bristol Myers Squibb Co., Cerulean Pharma, EMD Serono, Ergomed, Inc. Research, Inc., inVentiv Health Clinical PRA Intl, Ludwig Cancer Research, Merck and GenMab, New Mexico Cancer Care Alliance, Serono Inc., Stemcentrx, Inc; Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): Ambry, Arquer Diagnostics, Elevar, INXMED, Myriad Genetics, Novartis, Rubis, Roche Diagnostics MSA, Sorrento, Takeda, Tarveda and Toray, AbbVie, Agenus, Amgen, AstraZeneca, Celsion Corp, Clovis, Corcept Therapeutics, Eisai, GOG Foundation, Immunogen, Iovance, Janssen/Johnson & Johnson, Mersana, Novocure and Genentech/Roche, Regeneron, SDP Oncology (BBI), Seagen and Tesaro/GSK. All other authors have declared no conflicts of interest.
Resources from the same session
759P - Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Presenter: Junjie Wang
Session: Poster session 11
760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Presenter: Ang Qu
Session: Poster session 11
761P - A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Presenter: Josep M. Piulats
Session: Poster session 11
764P - Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
Presenter: JUN ZHU
Session: Poster session 11
765P - SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Presenter: Xiaohua Wu
Session: Poster session 11
766P - A comparative study of sequential and interdigitated brachytherapy with chemoradiation in patients of locally advanced carcinoma cervix
Presenter: Shreya Singh
Session: Poster session 11
767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer
Presenter: Ping Jiang
Session: Poster session 11
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11